Welltin 24 Tablet contains Betahistine 24 mg as its active ingredient, a histamine analogue primarily indicated for the treatment of Ménière’s disease and related vestibular disorders. Betahistine acts by improving microcirculation in the inner ear, thereby reducing endolymphatic pressure and alleviating symptoms such as vertigo, tinnitus, and hearing loss. The drug exerts its therapeutic effect through partial agonism of H1 histamine receptors and antagonism of H3 receptors, which enhances histaminergic neurotransmission and promotes vasodilation in the inner ear vasculature. Welltin 24 is typically administered orally and is well-absorbed from the gastrointestinal tract, with a favorable safety profile when used as directed. It is contraindicated in patients with pheochromocytoma and should be used cautiously in individuals with bronchial asthma or hypersensitivity to Betahistine or any excipients. Common adverse effects may include gastrointestinal disturbances such as nausea and abdominal discomfort, which are generally mild and transient. Welltin 24 Tablet should be used under medical supervision, with dosage adjustments based on clinical response and tolerability. It is not recommended during pregnancy or lactation unless clearly necessary. This medication offers an effective option for managing vestibular symptoms, improving patient quality of life in affected individuals.